“Many have called to ask us some more detail about the risk of the vaccine, whether what happened with that vaccine had anything to do with the one we are studying, these types of questions,” Borobia said in the interview. He did not say how many people had dropped out. This highlights the challenge for drugmakers in trialling potential vaccines to control the pandemic.
AstraZeneca’s trial was placed on hold globally on September 6 after a serious side effect was reported in a participant in the UK. Trials have restarted in Britain, South Africa and Brazil, but remain on hold in the US. Reuters